Table 1 Demographics of the JIA subgroups

Number of patients (% of total)

251 (N/A)

22 (8.8%)

112 (44.6%)

28 (11.2%)

84 (33.5%)

35 (13.9%)

17 (6.8%)

17 (6.8%)

7 (2.8%)

41 (16.3%)

Female (%)

66.5

36.4

69.6

67.9

70.2

74.3

70.6

76.5

57.1

63.4

Age at debut (years (25–75 centiles))

7.3 (2.3–11.5)

10.7 (6.5–13.2)

4.0 (2.0–9.9)

6.4 (1.9–10.3)

3.7 (2.0–9.7)

5.6 (1.9–11.2)

12.7 (10.7–14.5)

9.7 (5.5–12.2)

8.3 (3.1–9.5)

6 (2.8–11.8)

Follow-up time (years (25–75 centiles))

8 (6–11)

7 (6–11)

8 (6–11)

10 (7–13)

8 (6–10)

8 (7–11)

9 (7–12)

8 (5.5–10)

4 (1–6)

9 (7–11)

Disease duration at diagnosis (months (25–75 centiles))

5 (2–14)

9 (3.5–23.5)

5 (2–14)

9 (3–27)

4 (2–10)

6 (2–13)

5 (2–23)

14 (5.5–47.5)

2 (0–4)

4 (1–8.5)

ANA (%)*

50.6 (100)

27.2 (100)

67.9 (100)

53.6 (100)

72.6 (100)

48.6 (100)

23.5 (100)

23.5 (100)

14.3 (100)

46.3 (100)

RF (%)*

10.8 (90.0)

0 (90.9)

4.5 (89.3)

14.3 (92.9)

1.2 (88.1)

0 (94.3)

100 (100)

5.9 (82.4)

0 (85.7)

9.8 (87.8)

aCCP (%)*

6.8 (66.1)

4.5 (77.3)

1.8 (63.7)

7.1 (67.9)

0 (61.9)

2.9 (80.0)

70.6 (94.1)

0 (64.7)

0 (28.6)

2.4 (51.2)

HLAB27 (%)*

14.7 (45.0)

81.8 (90.9)

4.5 (34.8)

3.6 (42.9)

4.8 (32.1)

8.6 (54.3)

0 (35.3)

5.9 (41.2)

0 (14.3)

24.4 (51.2)